COLL
Collegium Pharmaceutical, Inc.
Platform & Compounding FCF
B
74.7 / 100 composite
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
-
5yr Avg ROIC
7.6%
-
Operating Margin Trend
+5.49 pp/yr
-
5yr Avg ROE
19.6%
-
5yr Share-Count CAGR
2.5%
-
5yr Revenue CAGR
20.3%
-
5yr EPS CAGR
17.9%
-
Revenue-Growth Years (5)
4/5
-
5yr FCF Margin
37.1%
-
5yr FCF/NI Conversion
3.82x
-
Net Debt / EBITDA
1.33x
-
Interest Coverage (EBIT/Int)
2.13x
-
Altman Z-Score
1.26
Stability
Weight: 5%
B-
64
-
EPS Volatility (σ/μ)
0.32
-
Negative-Revenue Years (5)
1/5
-
Piotroski F-Score
6
3 of 3 gurus held; 1 new buy; 1 added; 1 trimmed.
- Holders
- 3
+1
- Avg Δ position
-
+0.6%
- New buys
- 1
- Full exits
- 0